Icl670a Icl+Distab


Indications and Reactions:

Role Indications Reactions
Primary
Iron Overload 25.1%
Myelodysplastic Syndrome 19.2%
Prophylaxis 13.2%
Aplastic Anaemia 8.9%
Skin Ulcer 5.9%
Neurosis 4.7%
Diabetes Mellitus 2.9%
Haemosiderosis 2.6%
Myelofibrosis 2.2%
Blood Bilirubin Increased 1.9%
Porphyria Non-acute 1.9%
Infection Prophylaxis 1.8%
Hypertension 1.6%
Osteoporosis 1.5%
Aplasia Pure Red Cell 1.4%
Type 2 Diabetes Mellitus 1.3%
Insomnia 1.1%
Thalassaemia Beta 1.1%
Constipation Prophylaxis 0.9%
Liver Abscess 0.8%
White Blood Cell Count Increased 11.4%
Pyrexia 10.6%
Vomiting 10.6%
White Blood Cell Count Decreased 8.9%
Renal Impairment 7.6%
Pneumonia 6.4%
Renal Disorder 5.9%
Sepsis 5.1%
Serum Ferritin Increased 3.8%
Surgery 3.8%
Urinary Tract Infection 3.8%
Malignant Neoplasm Progression 3.4%
Vitrectomy 3.4%
Somnolence 2.5%
Staphylococcal Infection 2.5%
Gamma-glutamyltransferase Increased 2.1%
Platelet Count Decreased 2.1%
Renal Failure 2.1%
Viral Infection 2.1%
Hepatic Function Abnormal 1.7%
Secondary
Myelodysplastic Syndrome 17.2%
Iron Overload 16.9%
Aplastic Anaemia 12.9%
Prophylaxis 8.9%
Skin Ulcer 7.6%
Blood Bilirubin Increased 7.4%
Neurosis 6.0%
Haemosiderosis 4.0%
Diabetes Mellitus 3.3%
Porphyria Non-acute 2.4%
Gastroenteritis 2.3%
Myelofibrosis 1.7%
Osteoporosis 1.6%
Infection Prophylaxis 1.5%
Hypertension 1.4%
Constipation Prophylaxis 1.2%
Pain Prophylaxis 1.2%
Cardiac Failure Congestive 1.0%
Aplasia Pure Red Cell 0.7%
Insomnia 0.7%
Staphylococcal Infection 15.4%
White Blood Cell Count Increased 10.8%
Renal Impairment 7.2%
Unresponsive To Stimuli 7.2%
White Blood Cell Count Decreased 6.3%
Renal Failure 5.8%
Hepatic Function Abnormal 4.8%
Pyrexia 4.8%
Vitrectomy 4.6%
Shock Haemorrhagic 4.3%
Serum Ferritin Increased 4.1%
Renal Disorder 3.9%
Sepsis 3.6%
Skin Ulcer 2.9%
Pneumonia 2.7%
Urinary Tract Infection 2.7%
Malignant Neoplasm Progression 2.4%
Somnolence 2.2%
Surgery 2.2%
Vomiting 2.2%

Drug Data